CN103649104A - 用于制备氟替卡松丙酸酯形式1的方法 - Google Patents

用于制备氟替卡松丙酸酯形式1的方法 Download PDF

Info

Publication number
CN103649104A
CN103649104A CN201280034030.3A CN201280034030A CN103649104A CN 103649104 A CN103649104 A CN 103649104A CN 201280034030 A CN201280034030 A CN 201280034030A CN 103649104 A CN103649104 A CN 103649104A
Authority
CN
China
Prior art keywords
fluticasone propionate
solvent
solution
slurry
acetone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280034030.3A
Other languages
English (en)
Chinese (zh)
Inventor
M.D.泰斯赫斯特
I.马奇亚诺
E.库古洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Priority to CN201610951505.5A priority Critical patent/CN106977575A/zh
Publication of CN103649104A publication Critical patent/CN103649104A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280034030.3A 2011-07-08 2012-07-06 用于制备氟替卡松丙酸酯形式1的方法 Pending CN103649104A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610951505.5A CN106977575A (zh) 2011-07-08 2012-07-06 用于制备氟替卡松丙酸酯形式1的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505612P 2011-07-08 2011-07-08
US61/505,612 2011-07-08
PCT/US2012/045660 WO2013009591A1 (en) 2011-07-08 2012-07-06 Process for the preparation of fluticasone propionate form 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610951505.5A Division CN106977575A (zh) 2011-07-08 2012-07-06 用于制备氟替卡松丙酸酯形式1的方法

Publications (1)

Publication Number Publication Date
CN103649104A true CN103649104A (zh) 2014-03-19

Family

ID=47506422

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280034030.3A Pending CN103649104A (zh) 2011-07-08 2012-07-06 用于制备氟替卡松丙酸酯形式1的方法
CN201610951505.5A Pending CN106977575A (zh) 2011-07-08 2012-07-06 用于制备氟替卡松丙酸酯形式1的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610951505.5A Pending CN106977575A (zh) 2011-07-08 2012-07-06 用于制备氟替卡松丙酸酯形式1的方法

Country Status (10)

Country Link
US (2) US10370402B2 (cg-RX-API-DMAC7.html)
EP (1) EP2729480A4 (cg-RX-API-DMAC7.html)
JP (2) JP2014520848A (cg-RX-API-DMAC7.html)
KR (3) KR20140048237A (cg-RX-API-DMAC7.html)
CN (2) CN103649104A (cg-RX-API-DMAC7.html)
AU (1) AU2012282936B2 (cg-RX-API-DMAC7.html)
CA (1) CA2840401C (cg-RX-API-DMAC7.html)
MX (2) MX376564B (cg-RX-API-DMAC7.html)
WO (1) WO2013009591A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201309531B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376564B (es) * 2011-07-08 2025-03-07 Pfizer Ltd Proceso para la preparación de la forma 1 del propionato de fluticasona.
ES2727474T3 (es) 2012-05-08 2019-10-16 Nicox Ophthalmics Inc Nanocristales de propionato de fluticasona
US9796750B2 (en) 2014-02-07 2017-10-24 Mylan Laboratories Ltd. Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent
US20220168665A1 (en) * 2019-04-10 2022-06-02 Eupraxia Pharmaceuticals Inc. Process for making drug crystals of desired size distribution and morphology
CN110759960B (zh) * 2019-10-30 2021-03-23 山东赛托生物科技股份有限公司 一种丙酸氟替卡松的精制方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409627A (zh) * 1999-11-03 2003-04-09 葛兰素集团有限公司 制备晶粒的新装置和方法
WO2004001369A2 (en) * 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
CN100338087C (zh) * 2002-02-04 2007-09-19 葛兰素集团有限公司 制备氟替卡松丙酸酯,尤其是多晶型的晶形1的新方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
US7314516B2 (en) * 2004-12-29 2008-01-01 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization device and process
MX376564B (es) * 2011-07-08 2025-03-07 Pfizer Ltd Proceso para la preparación de la forma 1 del propionato de fluticasona.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409627A (zh) * 1999-11-03 2003-04-09 葛兰素集团有限公司 制备晶粒的新装置和方法
CN100338087C (zh) * 2002-02-04 2007-09-19 葛兰素集团有限公司 制备氟替卡松丙酸酯,尤其是多晶型的晶形1的新方法
WO2004001369A2 (en) * 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARTWIG STECKEL ET AL.: "In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS 》, vol. 258, 31 December 2003 (2003-12-31) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法

Also Published As

Publication number Publication date
MX2014000192A (es) 2014-04-25
US20200024298A1 (en) 2020-01-23
AU2012282936B2 (en) 2016-11-10
MX2020011330A (es) 2020-11-24
ZA201309531B (en) 2014-08-27
CA2840401C (en) 2016-05-17
JP2017031161A (ja) 2017-02-09
KR20140048237A (ko) 2014-04-23
CA2840401A1 (en) 2013-01-17
WO2013009591A1 (en) 2013-01-17
MX376564B (es) 2025-03-07
KR102163368B1 (ko) 2020-10-08
US20140141247A1 (en) 2014-05-22
CN106977575A (zh) 2017-07-25
US10370402B2 (en) 2019-08-06
KR20200117056A (ko) 2020-10-13
EP2729480A1 (en) 2014-05-14
AU2012282936A1 (en) 2014-01-16
KR20190107165A (ko) 2019-09-18
JP2014520848A (ja) 2014-08-25
EP2729480A4 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
US8765725B2 (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20200024298A1 (en) Process for the preparation of fluticasone propionate form i
JP4331619B2 (ja) 臭化チオトロピウムの結晶性微粒子
PT1981872T (pt) Sal de ácido succínico de éster 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-di-hidroquinolin-5-il)etilamino]metil]}-5-metoxifenilcarbamoil)etil]piperidin-4-ílico de ácido bifenil-2-ilcarbâmico e a sua utilização para o tratamento de distúrbios pulmonares
KR20140141596A (ko) 결정질 pi3 키나아제 저해제
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
JP2008534638A (ja) 新規な結晶性医薬製品
TW200418519A (en) Process for preparing crystalline CICLESONIDE with defined particle size
CN104955449A (zh) 用于吸入治疗的多组分结晶颗粒
Pitchayajittipong et al. Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid
EA008610B1 (ru) Суспензионные препараты на основе кристаллического ангидрата тиотропийбромида
CN106163505A (zh) 可吸入颗粒相关改进
CN112972384A (zh) 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
JP2007277228A (ja) アンドラストの新規で安定な結晶構造体
CN119925617A (zh) 一种用于治疗慢性阻塞性肺病(copd)的药物组合物及其制备方法
US20160045396A1 (en) Pulmonary Delivery of Progestogen
EP2022796A1 (en) Amorphous ciclesonide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140319